RESUMO
Evaluation of the stability of peptide drug candidates in biological fluids, such as blood serum, is of high importance during the lead optimisation phase. Here, we describe the optimisation and validation of a method for the evaluation of the stability of a lead calcitonin gene-related peptide antagonist peptide (P006) in blood serum. After initially determining appropriate peptide and human serum concentrations and selection of the quenching reagent, the HPLC method optimisation used two experimental designs, Plackett-Burman design and Taguchi design. The analytical method was validated as complying with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. The optimised method allowed the successful resolution of the parent peptide from its metabolites using RP-HPLC and identification of the major metabolites of P006 by mass spectrometry. This paradigm may be widely adopted as a robust early-stage platform for screening peptide stability to rule out candidates with low in vitro stability, which would likely translate into poor in vivo pharmacokinetics.
Assuntos
Antagonistas do Receptor do Peptídeo Relacionado ao Gene de Calcitonina , Peptídeo Relacionado com Gene de Calcitonina , Humanos , Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Cromatografia Líquida de Alta Pressão/métodos , Projetos de Pesquisa , Soro/metabolismoRESUMO
PURPOSE: Dry powder vaccine delivery via the pulmonary route has gained significant attention as an alternate route to parenteral delivery. In this study, we investigated bovine serum albumin (BSA) adsorbed poly(glycerol adipate-co-ω-pentadecalactone), PGA-co-PDL polymeric nanoparticles (NPs) within L-leucine (L-leu) microcarriers for dry powder inhalation. METHODS: NPs were prepared by oil-in-water single emulsion-solvent evaporation and particle size optimised using Taguchi's design of experiment. BSA was adsorbed onto NPs at different ratios at room temperature. The NPs were spray-dried in aqueous suspension of L-leu (1:1.5) using a Büchi-290 mini-spray dryer. The resultant nanocomposite microparticles (NCMPs) were characterised for toxicity (MTT assay), aerosolization (Next Generation Impactor), in vitro release study and BSA was characterized using SDS-PAGE and CD respectively. RESULTS: NPs of size 128.50 ± 6.57 nm, PDI 0.07 ± 0.03 suitable for targeting lung dendritic cells were produced. BSA adsorption for 1 h resulted in 10.23 ± 1.87 µg of protein per mg of NPs. Spray-drying with L-leu resulted in NCMPs with 42.35 ± 3.17% yield. In vitro release study at 37°C showed an initial burst release of 30.15 ± 2.33% with 95.15 ± 1.08% over 48 h. Aerosolization studies indicated fine particle fraction (FPF%) dae < 4.46 µm as 76.95 ± 5.61% and mass median aerodynamic diameter (MMAD) of 1.21 ± 0.67 µm. The cell viability was 87.01 ± 14.11% (A549 cell line) and 106.04 ± 21.14% (16HBE14o- cell line) with L-leu based NCMPs at 1.25 mg/ml concentration after 24 h treatment. The SDS-PAGE and CD confirmed the primary and secondary structure of the released BSA. CONCLUSIONS: The results suggest that PGA-co-PDL/L-leu NCMPs may be a promising carrier for pulmonary vaccine delivery due to excellent BSA adsorption and aerosolization behaviour.
Assuntos
Química Farmacêutica/métodos , Portadores de Fármacos/química , Nanopartículas/química , Poliésteres/química , Soroalbumina Bovina/administração & dosagem , Vacinas/administração & dosagem , Administração por Inalação , Adsorção , Aerossóis , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Dicroísmo Circular , Portadores de Fármacos/toxicidade , Liberação Controlada de Fármacos , Inaladores de Pó Seco , Eletroforese em Gel de Poliacrilamida , Humanos , Nanopartículas/toxicidade , Tamanho da Partícula , Poliésteres/toxicidade , Estabilidade Proteica , Propriedades de SuperfícieRESUMO
To accurately predict the in vivo performance of drugs from an in vitro dissolution test, the dissolution conditions used are supposed to be similar to those present in the gastrointestinal milieu. Post-prandial gastric fluid contains partially digested food mixtures consisting of fat, protein and carbohydrate. Despite this, the compendia dissolution medium recommended to simulate the gastric fluid is still composed of a simple solution of hydrochloric acid and sodium chloride with or without the addition of pepsin. Therefore, in this investigation, biorelevant dissolution media were developed to evaluate the impact of food constituents; milk with different fat contents, egg albumin, gelatin, casein, gluten, carbohydrates and amino acids on the intrinsic dissolution behavior of ketoconazole. Most of the food additives that were evaluated enhanced the apparent solubility of the drug but to different extents. The greatest enhancement in dissolution was observed in media containing either neutral amino acids or media based on milk mixtures. The formation of complexes between the drug and the additives most likely accounted for the solubilizing effect and in milk-containing media, the effect was attributed to the whole complex structure of milk rather than simply its fat content. These results highlight the potential effect of the type of ingested meal on drug dissolution and subsequent bioavailability.
Assuntos
Antifúngicos/química , Liberação Controlada de Fármacos , Interações Alimento-Droga , Cetoconazol/química , Modelos Biológicos , Disponibilidade Biológica , Carboidratos/química , Gorduras/química , Concentração de Íons de Hidrogênio , Proteínas/química , SolubilidadeRESUMO
Abstract Poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL) was previously evaluated for the colloidal delivery of α-chymotrypsin. In this article, the effect of varying polymer molecular weight (MW) and chemistry on particle size and morphology; encapsulation efficiency; in vitro release; and the biological activity of α-chymotrypsin (α-CH) and lysozyme (LS) were investigated. Microparticles were prepared using emulsion solvent evaporation and evaluated by various methods. Altering the MW or monomer ratio of PGA-co-PDL did not significantly affect the encapsulation efficiency and overall poly(1,3-propanediol adipate-co-ω-pentadecalactone) (PPA-co-PDL) demonstrated the highest encapsulation efficiency. In vitro release varied between polymers, and the burst release for α-CH-loaded microparticles was lower when a higher MW PGA-co-PDL or more hydrophobic PPA-co-PDL was used. The results suggest that, although these co-polyesters could be useful for protein delivery, little difference was observed between the different PGA-co-PDL polymers and PPA-co-PDL generally provided a higher encapsulation and slower release of enzyme than the other polymers tested.
Assuntos
Quimotripsina/química , Lactonas/química , Poliésteres/química , Polímeros/química , Proteínas/química , Sistemas de Liberação de Medicamentos/métodos , Emulsões/química , Macrolídeos/química , Microesferas , Peso Molecular , Muramidase/química , Tamanho da Partícula , Propilenoglicóis/químicaRESUMO
Pulmonary vaccine delivery has gained significant attention as an alternate route for vaccination without the use of needles. Immunization through the pulmonary route induces both mucosal and systemic immunity, and the delivery of antigens in a dry powder state can overcome some challenges such as cold-chain and availability of medical personnel compared to traditional liquid-based vaccines. Antigens formulated as nanoparticles (NPs) reach the respiratory airways of the lungs providing greater chance of uptake by relevant immune cells. In addition, effective targeting of antigens to the most 'professional' antigen presenting cells (APCs), the dendritic cells (DCs) yields an enhanced immune response and the use of an adjuvant further augments the generated immune response thus requiring less antigen/dosage to achieve vaccination. This review discusses the pulmonary delivery of vaccines, methods of preparing NPs for antigen delivery and targeting, the importance of targeting DCs and different techniques involved in formulating dry powders suitable for inhalation.
Assuntos
Antígenos/administração & dosagem , Células Dendríticas/imunologia , Sistemas de Liberação de Medicamentos/métodos , Pulmão/imunologia , Nanoestruturas/química , Vacinas/administração & dosagem , Administração por Inalação , Animais , Antígenos/uso terapêutico , Liofilização/métodos , Humanos , Pulmão/anatomia & histologia , Nanotecnologia/métodos , Polímeros/química , Vacinas/uso terapêuticoRESUMO
OBJECTIVES: It has previously been shown that the peptide (34Pro,35Phe)CGRP27-37 is a potent calcitonin gene-related peptide, CGRP receptor antagonist, and in this project we aimed to improve the antagonist potency through the structural modification of truncated C-terminal CGRP peptides. METHODS: Six peptide analogues were synthesized and the anti-CGRP activity confirmed using both in vitro and in vivo studies. KEY FINDINGS: A 10 amino acid-containing peptide VPTDVGPFAF-NH2 (P006) was identified as a key candidate to take forward for in vivo evaluation, where it was shown to be an effective antagonist after intraperitoneal injection into mice. P006 was formulated as a preparation suitable for nasal administration by spray drying with chitosan to form mucoadhesive microcarriers (9.55 ± 0.91 mm diameter) and a loading of 0.2 mg peptide per 20 mg dose. CONCLUSIONS: The project has demonstrated the potential of these novel small peptide CGRP antagonists, to undergo future preclinical evaluation as anti-migraine therapeutics.
Assuntos
Peptídeo Relacionado com Gene de Calcitonina , Transtornos de Enxaqueca , Camundongos , Animais , Peptídeo Relacionado com Gene de Calcitonina/uso terapêutico , Receptores de Peptídeo Relacionado com o Gene de Calcitonina , Antagonistas do Receptor do Peptídeo Relacionado ao Gene de Calcitonina/farmacologia , Aminoácidos/química , Transtornos de Enxaqueca/tratamento farmacológicoRESUMO
As of 2020, there were >100 approved peptides with therapeutic or diagnostic applications. However, a complete database providing information on marketed peptides is not freely available, making the peptide chemists' job of designing future peptide drug candidates challenging. Unlike the rules for small-molecule drugs, there is no general set of guidelines for designing a successful peptide-based drug. In this review, together with our freely available database (PepTherDia, http://peptherdia.herokuapp.com), we provide insights into what a successful peptide therapeutic or diagnostic agent looks like and lay the foundation for establishing a set of rules to help future medicinal chemists to design peptide candidates with increased approval rates.
Assuntos
Bases de Dados Factuais , Desenho de Fármacos , Peptídeos/administração & dosagem , Química Farmacêutica/métodos , Aprovação de Drogas , Humanos , Peptídeos/química , Peptídeos/farmacologiaRESUMO
Biochemical and physiological tests, and 16S rRNA gene sequences, were used to classify nine Actinomycete strains isolated from soil and sand samples in Thailand. These strains were isolated based on their ability to readily degrade mucin glycoproteins. A turbidometric based mucinolytic assay was developed to confirm this. In addition all strains showed significant production of proteases. Phylogenetic analysis of the strains revealed that from the nine isolated Actinomycete strains eight were closely related to Streptomyces species and one was identified as belonging to the genus Kitasatospora. The biochemical and physiological tests performed identified two strain pairs that were similar (with only 3.9% difference observed) and this was in accordance with the phylogenetic results obtained. The remaining strains were distinct from each other, with the soil-isolated strains forming a separate clade to the sand-isolated strains in the inferred phylogenetic trees. The isolated mucinolytic Actinomycete strains will be the subject of further investigations into their proteolytic and glycosidic activity. Mucin degrading enzymes such as these are studied for their potential to be used for the development of a drug delivery system.
Assuntos
Actinobacteria/classificação , Actinobacteria/metabolismo , Mucinas/metabolismo , Microbiologia do Solo , Actinobacteria/genética , Actinobacteria/isolamento & purificação , Técnicas de Tipagem Bacteriana , Análise por Conglomerados , DNA Bacteriano/química , DNA Bacteriano/genética , DNA Ribossômico/química , DNA Ribossômico/genética , Dados de Sequência Molecular , Filogenia , RNA Ribossômico 16S/genética , Análise de Sequência de DNA , TailândiaRESUMO
OBJECTIVES: To investigate the formulation of the peptide-based antagonist (34 Pro,35 Phe)CGRP27-37 , of the human calcitonin gene-related peptide (CGRP) receptor as a potential nasally delivered migraine treatment. METHODS: Peptide sequences were prepared using automated methods and purified by preparative HPLC. Their structure and stability were determined by LC-MS. Antagonist potency was assessed by measuring CGRP-stimulated cAMP accumulation in SK-N-MC, cells and in CHO cells overexpressing the human CGRP receptor. In vivo activity was tested in plasma protein extravasation (PPE) studies using Evans blue dye accumulation. Peptide-containing chitosan microparticles were prepared by spray drying. KEY FINDINGS: (34 Pro,35 Phe)CGRP27-37 exhibited a 10-fold increased affinity compared to αCGRP27-37 . Administration of (34 Pro,35 Phe)CGRP27-37 to mice led to a significant decrease in CGRP-induced PPE confirming antagonistic properties in vivo. There was no degradation of (34 Pro,35 Phe)CGRP27-37 and no loss of antagonist potency during formulation and release from chitosan microparticles. CONCLUSIONS: (34 Pro,35 Phe)CGRP27-37 is a potent CGRP receptor antagonist both in vitro and in vivo, and it can be formulated as a dry powder with no loss of activity indicating its potential as a nasally formulated anti-migraine medicine.
Assuntos
Antagonistas do Receptor do Peptídeo Relacionado ao Gene de Calcitonina/administração & dosagem , Antagonistas do Receptor do Peptídeo Relacionado ao Gene de Calcitonina/metabolismo , Composição de Medicamentos/métodos , Transtornos de Enxaqueca/tratamento farmacológico , Transtornos de Enxaqueca/metabolismo , Receptores de Peptídeo Relacionado com o Gene de Calcitonina/metabolismo , Administração Intranasal , Animais , Células CHO , Antagonistas do Receptor do Peptídeo Relacionado ao Gene de Calcitonina/síntese química , Linhagem Celular Tumoral , Cricetinae , Cricetulus , Relação Dose-Resposta a Droga , Camundongos , Camundongos Endogâmicos C57BLRESUMO
Drugs in the gastrointestinal tract are exposed to a medium of partially digested food, comprising mixtures of fat, protein and carbohydrate. The dissolution behaviour of itraconazole was evaluated in bio-relevant media which were developed to take this into account. Media containing milk with different fat contents, protein (albumin, casein, gluten and gelatin), carbohydrates (glucose, lactose and starch) and amino acids (lysine, glycine, alanine and aspartic acid) to mimic a digested meal and bile components (sodium taurocholate and lecithin) to represent a key endogenous digestive material were investigated. The effect of medium composition on the intrinsic dissolution rate of itraconazole was evaluated as this drug has extremely poor solubility and its bioavailability is affected by food. Dissolution tests were carried out in simple compendial media based on dilute solutions of hydrochloric acid or neutral solutions of phosphate buffer and in more complex media containing the dietary components. The data obtained showed that most of the dietary components enhanced the solubility compared to simulated gastric fluid (SGF) but to differing extents. The greatest increase in dissolution was observed with the addition of milk and albumin although an increase was also seen with other proteins, amino acids and simulated gastrointestinal fluids.
Assuntos
Antifúngicos/química , Interações Alimento-Droga , Itraconazol/química , Aminoácidos/metabolismo , Animais , Antifúngicos/farmacocinética , Bile/química , Disponibilidade Biológica , Carboidratos da Dieta/metabolismo , Gorduras na Dieta/metabolismo , Proteínas Alimentares/metabolismo , Suco Gástrico/metabolismo , Secreções Intestinais/metabolismo , Itraconazol/farmacocinética , Leite/metabolismo , SolubilidadeRESUMO
The treatment and management of COPD by inhalation to the lungs has emerged as an attractive alternative route to oral dosing due to higher concentrations of the drug being administered to site of action. In this study, Nanocomposite Microparticles (NCMPs) of microRNA (miR-146a) containing PGA-co-PDL nanoparticles (NPs) for dry powder inhalation were formulated using l-leucine and mannitol. The spray-drying (Buchi B290) process was optimised and used to incorporate NPs into NCMPs using mix of l-leucine and mannitol excipients in different ratios (F1; 100:0% w/w, F2; 75:25% w/w, F3; 50:50% w/w, F4; 25:75% w/w, F5; 0:100% w/w) to investigate yield %, moisture content, aerosolisation performance and miR-146a biological activity. The optimum condition was performed at feed rate 0.5â¯ml/min, aspirator rate 28â¯m3/h, atomizing air flow rate 480â¯L/h, and inlet drying temperature 70⯰C which produced highest yield percentage and closest recovered NPs size to original prior spray-drying. The optimum formulation (F4) had a high yield (86.0⯱â¯15.01%), recovered NPs size after spray-drying 409.7⯱â¯10.05â¯nm (initial NPs size 244.8⯱â¯4.40â¯nm) and low moisture content (2.02⯱â¯0.03%). The aerosolisation performance showed high Fine Particle Fraction (FPF) 51.33⯱â¯2.9%, Emitted Dose (ED) of 81.81⯱â¯3.0%, and the mass median aerodynamic diameter (MMAD) was ≤5⯵m suggesting a deposition in the respirable region of the lungs. The biological activity of miR-146a was preserved after spray-drying process and miR-146a loaded NCMPs produced target genes IRAK1 and TRAF6 silencing. These results indicate the optimal process parameters for the preparation of NCMPs of miR-146a-containing PGA-co-PDL NPs suitable for inhalation in the treatment and management of COPD.
Assuntos
Portadores de Fármacos/administração & dosagem , MicroRNAs/administração & dosagem , Nanocompostos/administração & dosagem , Poliésteres/administração & dosagem , Células A549 , Administração por Inalação , Aerossóis , Portadores de Fármacos/química , Excipientes/administração & dosagem , Excipientes/química , Humanos , Quinases Associadas a Receptores de Interleucina-1/genética , Leucina/administração & dosagem , Leucina/química , Manitol/administração & dosagem , Manitol/química , MicroRNAs/química , Nanocompostos/química , Poliésteres/química , Pós , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológicoRESUMO
The application of natural products to treat various diseases, such as cancer, has been an important area of research for many years. Several phytochemicals have demonstrated anticarcinogenic activity to prevent or reduce the progression of cancer by modulating various cellular mechanisms. However, poor bioavailability has hindered clinical success and the incorporation of these drugs into efficient drug delivery systems would be beneficial. For lung cancer, local delivery via the pulmonary route would also be more effective. In this article, recent in vitro scientific literature on phenolic compounds with anticancer activity towards lung cancer cell lines is reviewed and nanoparticulate delivery is mentioned as a possible solution to the problem of bioavailability. The first part of the review will explore the different classes of natural phenolic compounds and discuss recent reports on their activity on lung cancer cells. Then, the problem of the poor bioavailability of phenolic compounds will be explored, followed by a summary of recent advances in improving the efficacy of these phenolic compounds using nanoparticulate drug delivery systems. Graphical abstract The rationale for direct delivery of phenolic compounds loaded in microparticles to the lungs.
Assuntos
Neoplasias Pulmonares/tratamento farmacológico , Fenóis/farmacocinética , Compostos Fitoquímicos/farmacocinética , Disponibilidade Biológica , Linhagem Celular Tumoral , Sistemas de Liberação de Medicamentos , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Fenóis/química , Compostos Fitoquímicos/químicaRESUMO
RNA interference (RNAi) based therapeutics are considered an endogenous mechanism for modulating gene expression. In addition, microRNAs (miRNAs) may be tractable targets for the treatment of Chronic Obstructive Pulmonary Disease (COPD). In this study miR146a was adsorbed onto poly (glycerol adipate-co-ω-pentadecalactone), PGA-co-PDL, nanoparticles (NPs) to reduce target gene IRAK1 expression. NPs were prepared using an oil-in-water single emulsion solvent evaporation method incorporating cationic lipid dioleoyltrimethylammoniumpropane (DOTAP). This resulted in NPs of 244.80⯱â¯4.40â¯nm at 15% DOTAP concentration, zeta potential (ZP) of +14.8⯱â¯0.26â¯mV and miR-146a (40⯵g/ml) maximum adsorption onto 15% DOTAP NPs was 36.25⯱â¯0.35⯵g per 10â¯mg NP following 24â¯h incubation. Using the MTT assay, it was observed that over 75% at 0.312â¯mg/ml of A549 cells remained viable after 18â¯h exposure to cationic NPs at a concentration of 1.25â¯mg/ml. Furthermore, the in vitro release profile of miR-146a from loaded NPs showed a continuous release up to 77% after 24â¯h. Internalization of miR-146a loaded cationic NPs was observed in A549 cell lines using fluorescence and confocal microscopy. The miR146a delivered as miR-146a-NPs had a dose dependent effect of highest NPs concentrations 0.321 and 0.625â¯mg/ml and reduced target gene IRAK1 expression to 40%. In addition, IL-8 promoter reporter output (GFP) was dampened by miR-146a-NPs. In conclusion, miR-146a was successfully adsorbed onto PGA-co-PDL-DOTAP NPs and the miR-146a retained biological activity. Therefore, these results demonstrate the potential of PGA-co-PDL NPs as a delivery system for miR-146a to treat COPD.
Assuntos
Sistemas de Liberação de Medicamentos/métodos , Ácidos Graxos Monoinsaturados/administração & dosagem , MicroRNAs/administração & dosagem , Nanopartículas/administração & dosagem , Poliésteres/administração & dosagem , Doença Pulmonar Obstrutiva Crônica , Compostos de Amônio Quaternário/administração & dosagem , Células A549 , Relação Dose-Resposta a Droga , Ácidos Graxos Monoinsaturados/metabolismo , Humanos , MicroRNAs/metabolismo , Nanopartículas/metabolismo , Tamanho da Partícula , Poliésteres/metabolismo , Polímeros/administração & dosagem , Polímeros/metabolismo , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Doença Pulmonar Obstrutiva Crônica/metabolismo , Compostos de Amônio Quaternário/metabolismoRESUMO
In this study, Taguchi design was used to determine optimal parameters for the preparation of bovine serum albumin (BSA)-loaded nanoparticles (NPs) using a biodegradable polymer poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL). NPs were prepared, using BSA as a model protein, by the double emulsion evaporation process followed by spray-drying from leucine to form nanocomposite microparticles (NCMPs). The effect of various parameters on NP size and BSA loading were investigated and dendritic cell (DC) uptake and toxicity. NCMPs were examined for their morphology, yield, aerosolisation, in vitro release behaviour and BSA structure. NP size was mainly affected by the polymer mass used and a small particle size ≤500 nm was achieved. High BSA (43.67 ± 2.3 µg/mg) loading was influenced by BSA concentration. The spray-drying process produced NCMPs (50% yield) with a porous corrugated surface, aerodynamic diameter 1.46 ± 141 µm, fine particle dose 45.0 ± 4.7 µg and fine particle fraction 78.57 ± 0.1%, and a cumulative BSA release of 38.77 ± 3.0% after 48 h. The primary and secondary structures were maintained as shown by sodium dodecyl sulphate poly (acrylamide) gel electrophoresis and circular dichroism. Effective uptake of NPs was seen in DCs with >85% cell viability at 5 mg/mL concentration after 4 h. These results indicate the optimal process parameters for the preparation of protein-loaded PGA-co-PDL NCMPs suitable for inhalation.
Assuntos
Portadores de Fármacos/química , Pulmão/metabolismo , Nanocompostos/administração & dosagem , Nanocompostos/química , Nanopartículas/química , Proteínas/administração & dosagem , Proteínas/química , Administração por Inalação , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Dicroísmo Circular/métodos , Células Dendríticas/metabolismo , Portadores de Fármacos/administração & dosagem , Eletroforese em Gel de Poliacrilamida/métodos , Emulsões/química , Humanos , Microesferas , Nanopartículas/administração & dosagem , Tamanho da Partícula , Poliésteres/química , Polímeros/química , Soroalbumina Bovina/administração & dosagem , Soroalbumina Bovina/química , Propriedades de SuperfícieRESUMO
Pulmonary delivery of macromolecules has been the focus of attention as an alternate route of delivery with benefits such as; large surface area, thin alveolar epithelium, rapid absorption and extensive vasculature. In this study, a model protein, bovine serum albumin (BSA) was adsorbed onto cationic PGA-co-PDL polymeric nanoparticles (NPs) prepared by a single emulsion solvent evaporation method using a cationic surfactant didodecyldimethylammonium bromide (DMAB) at 2% w/w (particle size: 128.64±06.01 nm and zeta-potential: +42.32±02.70 mV). The optimum cationic NPs were then surface adsorbed with BSA, NP:BSA (100:4) ratio yielded 10.01±1.19 µg of BSA per mg of NPs. The BSA adsorbed NPs (5 mg/ml) were then spray-dried in an aqueous suspension of L-leucine (7.5 mg/ml, corresponding to a ratio of 1:1.5/NP:L-leu) using a Büchi-290 mini-spray dryer to produce nanocomposite microparticles (NCMPs) containing cationic NPs. The aerosol properties showed a fine particle fraction (FPF, dae<4.46 µm) of 70.67±4.07% and mass median aerodynamic diameter (MMAD) of 2.80±0.21 µm suggesting a deposition in the respiratory bronchiolar region of the lungs.The cell viability was 75.76±03.55% (A549 cell line) at 156.25 µg/ml concentration after 24 h exposure. SDS-PAGE and circular dichroism (CD) confirmed that the primary and secondary structure of the released BSA was maintained. Moreover, the released BSA showed 78.76±1.54% relative esterolytic activity compared to standard BSA.
Assuntos
Nanopartículas/química , Poliésteres/química , Soroalbumina Bovina/química , Administração por Inalação , Adsorção , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Dicroísmo Circular , Liberação Controlada de Fármacos , Eletroforese em Gel de Poliacrilamida , Humanos , Microscopia Eletrônica de Transmissão , Nanopartículas/administração & dosagem , Nanopartículas/ultraestrutura , Poliésteres/administração & dosagem , Pós , Estabilidade Proteica , Compostos de Amônio Quaternário/química , Soroalbumina Bovina/administração & dosagem , Propriedades de Superfície , Tensoativos/químicaRESUMO
Pneumonia, caused by Streptococcus pneumoniae, mainly affects the immunocompromised, the very young and the old, and remains one of the leading causes of death. A steady rise in disease numbers from non-vaccine serotypes necessitates a new vaccine formulation that ideally has better antigen stability and integrity, does not require cold-chain and can be delivered non-invasively. In this study, a dry powder vaccine containing an important antigen of S. pneumoniae, pneumococcal surface protein A (PspA) that has shown cross-reactivity amongst serotypes to be delivered via the pulmonary route has been formulated. The formulation contains the antigen PspA adsorbed onto the surface of polymeric nanoparticles encapsulated in L-leucine microparticles that can be loaded into capsules and delivered via an inhaler. We have successfully synthesized particles of â¼150 nm and achieved â¼20 µg of PspA adsorption per mg of NPs. In addition, the spray-dried powders displayed a FPF of 74.31±1.32% and MMAD of 1.70±0.03 µm suggesting a broncho-alveolar lung deposition facilitating the uptake of the nanoparticles by dendritic cells. Also, the PspA released from the dry powders maintained antigen stability (SDS-PAGE), integrity (Circular dichroism) and activity (lactoferrin binding assay). Moreover, the released antigen also maintained its antigenicity as determined by ELISA.
Assuntos
Antígenos de Bactérias/administração & dosagem , Proteínas de Bactérias/administração & dosagem , Proteínas de Bactérias/imunologia , Vacinas Bacterianas/administração & dosagem , Pulmão/metabolismo , Nanopartículas/administração & dosagem , Pós/administração & dosagem , Administração por Inalação , Adsorção , Antígenos de Bactérias/imunologia , Vacinas Bacterianas/imunologia , Sobrevivência Celular , Química Farmacêutica/métodos , Células Dendríticas/imunologia , Liberação Controlada de Fármacos , Estabilidade de Medicamentos , Humanos , Lactoferrina/imunologia , Pulmão/citologia , Nanopartículas/efeitos adversos , Tamanho da PartículaRESUMO
This study investigated optimizing the formulation parameters for encapsulation of a model mucinolytic enzyme, α-chymotrypsin (α-CH), within a novel polymer; poly(ethylene glycol)-co-poly(glycerol adipate-co-ω-pentadecalactone), PEG-co-(PGA-co-PDL) which were then applied to the formulation of DNase I. α-CH or DNase I loaded microparticles were prepared via spray drying from double emulsion (w(1)/o/w(2)) utilizing chloroform (CHF) as the organic solvent, L-leucine as a dispersibility enhancer and an internal aqueous phase (w(1)) containing PEG4500 or Pluronic(®) F-68 (PLF68). α-CH released from microparticles was investigated for bioactivity using the azocasein assay and the mucinolytic activity was assessed utilizing the degradation of mucin suspension assay. The chemical structure of PEG-co-(PGA-co-PDL) was characterized by (1)H NMR and FT-IR with both analyses confirming PEG incorporated into the polymer backbone, and any unreacted units removed. Optimum formulation α-CH-CHF/PLF68, 1% produced the highest bioactivity, enzyme encapsulation (20.08±3.91%), loading (22.31±4.34 µg/mg), FPF (fine particle fraction) (37.63±0.97%); FPD (fine particle dose) (179.88±9.43 µg), MMAD (mass median aerodynamic diameter) (2.95±1.61 µm), and the mucinolytic activity was equal to the native non-encapsulated enzyme up to 5h. DNase I-CHF/PLF68, 1% resulted in enzyme encapsulation (17.44±3.11%), loading (19.31±3.27 µg/mg) and activity (81.9±2.7%). The results indicate PEG-co-(PGA-co-PDL) can be considered as a potential biodegradable polymer carrier for dry powder inhalation of macromolecules for treatment of local pulmonary diseases.
Assuntos
Quimotripsina/administração & dosagem , Desoxirribonuclease I/administração & dosagem , Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos , Administração por Inalação , Animais , Brônquios/citologia , Brônquios/metabolismo , Quimotripsina/farmacologia , Desoxirribonuclease I/farmacologia , Inaladores de Pó Seco , Emulsões , Células Epiteliais/metabolismo , Humanos , Microesferas , Mucinas/metabolismo , Tamanho da Partícula , Poloxâmero/química , Poliésteres/química , Polietilenoglicóis/química , Suínos , Fatores de TempoRESUMO
Polymer-based microparticles are increasingly becoming of interest for a variety of applications including drug delivery. Recently poly(glycerol adipate) (PGA) and poly(glycol adipate-co-omega-pentadecalactone) have shown promise for delivery of dexamethasone phosphate and ibuprofen. In this paper the copolyester poly(glycol adipate-co-omega-pentadecalactone) was evaluated as a colloidal delivery system for encapsulated therapeutic proteins. Enzyme containing microparticles were prepared via the double water-in-oil-in-water (w/o/w) emulsion-solvent evaporation methodology. alpha-Chymotrypsin was used as a model proteolytic enzyme and its transfer was monitored during the emulsification process, in addition to in vitro release from formed particles. On average, 22.1 microg protein per 1 mg polymer was encapsulated, although gradual loss of activity of the protein, once released, was recorded. The work presented shows the potential of this polyester as a delivery system for enzymes via microparticles, with improvements to the system achievable via polymer and process optimization. The pendant hydroxyl groups on the polymer backbone provide future capacity for tailored alteration of the physical and chemical properties of the polymer, in addition to covalent attachment of various compounds.
Assuntos
Quimotripsina/química , Quimotripsina/farmacocinética , Microesferas , Materiais Biocompatíveis/química , Caseínas/química , Quimotripsina/administração & dosagem , Dexametasona/administração & dosagem , Sistemas de Liberação de Medicamentos , Ibuprofeno/administração & dosagem , Espectroscopia de Ressonância Magnética , Microscopia Eletrônica de Varredura , Modelos Biológicos , Tamanho da Partícula , Fosfatos/administração & dosagem , Poliésteres/química , Polímeros/química , Espectrofotometria Ultravioleta/métodosRESUMO
We have previously demonstrated the ability of poly(glycerol adipate) backbone (PGA) and PGA polymer backbone substituted with varying amounts of pendant C(18) chain length acyl groups to yield Dexamethasone phosphate DXMP loaded nanoparticles. The aim of this study was to obtain a deeper understanding of the underlying principles responsible for good drug incorporation and controlled release of drugs from poly (glycerol adipate) (PGA) nanoparticles. We compared the incorporation of the water soluble drugs DXMP and Cytosine arabinoside (CYT-ARA) in both unmodified and substituted PGA polymers. We investigated the effect of change in acyl group chain length and the degree of substitution on the physicochemical properties, drug loading and release of DXMP and CYT-ARA. Nanoparticles were prepared by the interfacial deposition technique and the simultaneous emulsification method. Amongst the nanoparticles prepared using acylated polymers with varying chain lengths (C(2) to C(10)) for DXMP incorporation, polymers with acyl group chain lengths containing 8 carbon atoms (C(8)) showed maximum drug incorporation. Amongst the C(8) series, polymers with 100% acylation provided both good drug incorporation and a controlled release for DXMP while for CYT-ARA it was the unsubstituted polymer backbone that had maximum drug loading and slower release. A number of inter-related factors are responsible for producing particles with particular size, zeta potential, drug loading and release characteristics. Drug loading and release from nanoparticles are primarily influenced by the nature of interactions between the drug and polymers which in turn depend upon the type of drug used and the physical chemistry of the polymer.
Assuntos
Portadores de Fármacos/química , Nanopartículas/química , Preparações Farmacêuticas/administração & dosagem , Poliésteres/química , Citarabina/administração & dosagem , Citarabina/química , Dexametasona/administração & dosagem , Dexametasona/análogos & derivados , Dexametasona/química , Composição de Medicamentos , Microscopia Eletrônica de Transmissão , Tamanho da Partícula , Preparações Farmacêuticas/química , Solubilidade , ÁguaRESUMO
A simple and effective method is described for the preparation of enzyme-containing materials that possess excellent catalytic activity, mechanical strength, and reusability. Uniform spherical beads were produced via the colyophilization of alpha-chymotrypsin with the support materials, leaving the active enzyme entrapped within the porous "ice-templated" support matrix. The composites were assayed for catalytic activity by monitoring a nonaqueous transesterification reaction. The mechanical strength for each composite was measured using a compression assay. Initial screens identified a set of six support materials that contributed favorably to either the enzyme activity or to the mechanical strength of the composite. A design of experiments (DoE) methodology was employed to screen 80 combinations of these six "base" materials. A model representing this formulation space was constructed which could be used to predict both the catalytic activity and mechanical strength with reasonable accuracy for any combination of the six base component materials. This model was used to predict optimized materials with an enzyme activity that was 50 times greater than that of the free enzyme. The model was also used to set a minimum acceptable mechanical stability for these composites, and the resulting materials were shown to be reusable for at least ten reaction cycles.